Table 3.
Correlations of rs4646 and clinical variables.
| Variable | CYP19 gene rs4646 (n = 136) | |||
|---|---|---|---|---|
|
| ||||
| n | WT, n (%) | Variant, n (%) | p | |
| Histological diagnosis | ||||
| IDC | 194 | 98 (72.1) | 96 (70.6) | 1.000 |
| ILC | 38 | 20 (14.7) | 18 (13.2) | |
| Others | 40 | 18 (13.2) | 22 (16.2) | |
| ECOG performance status | ||||
| 0 | 156 | 76 (55.9) | 80 (58.8) | 1.000 |
| 1–2 | 116 | 60 (44.1) | 56 (41.2) | |
| BMI level | ||||
| ≤24 | 161 | 75 (55.1) | 86 (63.2) | 1.000 |
| >24 | 111 | 61 (44.9) | 50 (36.8) | |
| No. of metastatic locations | ||||
| ≤3 | 173 | 95 (69.9) | 78 (57.4) | 1.000 |
| >3 | 99 | 41 (30.1) | 58 (42.6) | |
| HER2 status | ||||
| Negative | 176 | 84 (61.8) | 92 (67.6) | 1.000 |
| Positive | 96 | 52 (38.2) | 44 (32.4) | |
| Trastuzumab therapy history | ||||
| Yes | 36 | 16 (30.8) | 20 (45.5) | 1.000 |
| No | 60 | 36 (69.2) | 24 (54.5) | |
| Family history | ||||
| No | 180 | 80 (58.8) | 100 (73.5) | 1.000 |
| Yes | 92 | 56 (41.2) | 36 (26.5) | |
| ER status | ||||
| ER+/PR+ | 196 | 96 (70.6) | 100 (73.5) | 1.000 |
| ER+/PR− | 52 | 24 (17.6) | 28 (20.6) | |
| ER−/PR+ | 24 | 16 (11.8) | 8 (5.9) | |
Note: WT, wild-type (GG); variant, heterozygous or homozygous for the SNP rs4646 (GT or TT).